Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC

Inclusion Criteria: Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent 18 years of age or older Histologically confirmed cT1c-T3 N0 or cT1-T3 N1-N2 triple-negative breast cancer * The invasive tumor must be hormone receptor poor, defined as both estrogen receptor (ER) and progesterone receptor staining in ≤ 10% of invasive cancer cells by IHC. * The invasive tumor must be HER2-negative based on the current ASCO-CAP guidelines 79. * Subjects with bilateral synchronous triple-negative breast cancer are eligible if they meet other eligibility criteria. No previous ipsilateral breast surgery for the current breast cancer No previous chemotherapy, immunotherapy, targeted therapy, endocrine therapy, or radiotherapy for the current breast cancer ECOG Performance Status 0 or 1, documented within 21 days prior to the start of study treatment (Appendix A) Breast and axillary imaging (including MRI and either mammogram and/or ultrasound, per standard of care) within 56 days (8 weeks) prior to treatment initiation Subjects with clinically and/or radiographically abnormal axillary or internal mammary lymph nodes should have pathologic assessment of disease status with image-guided biopsy or fine needle aspiration unless deemed medically unsafe Co-enrollment in the PROGECT (HSC #12614) observational registry protocol Archival breast tumor tissue has been obtained or has…